Wedbush Maintains Outperform on Zentalis Pharma, Raises Price Target to $38
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Robert Driscoll maintains an Outperform rating on Zentalis Pharma (NASDAQ:ZNTL) and raises the price target from $31 to $38.
May 26, 2023 | 1:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst maintains Outperform rating on Zentalis Pharma and raises price target from $31 to $38.
The news of Wedbush analyst Robert Driscoll maintaining an Outperform rating on Zentalis Pharma and raising the price target from $31 to $38 is positive for the company. This indicates that the analyst has a positive outlook on the company's performance and potential growth, which could lead to an increase in investor confidence and a potential short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100